T6SS mutants exploit itaconate to support infection of phagocytes

This study demonstrates that *Pseudomonas aeruginosa* variants lacking the H3-T6SS exploit host-derived itaconate to enhance their metabolic fitness and survival within phagolysosomes, thereby facilitating persistent pulmonary infections.

The Gist

The Big Picture: A Bacterial "Camouflage" Strategy

Imagine your lungs as a busy city. When the bacteria Pseudomonas aeruginosa invades, the city's security guards (your immune cells, specifically macrophages) rush to the scene to capture and destroy the intruders.

Usually, these bacteria have a "super-weapon" called the H3-T6SS. Think of this weapon like a giant, noisy flamethrower. In the early stages of an infection, this flamethrower helps the bacteria fight off other bacteria and scare off the immune system.

However, this study discovered something surprising: In chronic (long-lasting) infections, the bacteria actually throw away their flamethrower.

Instead of fighting, they change their strategy. They lose the flamethrower (the H3-T6SS) and put on a "stealth suit." This allows them to sneak inside the very security guards meant to kill them and hide out safely.

The Secret Ingredient: "Itaconate"

To understand how this works, we need to meet a special chemical called Itaconate.

• What is it? When your immune cells fight an infection, they pump out itaconate like a fire extinguisher foam. It's meant to stop the bacteria.
• The Twist: The bacteria that lost their "flamethrower" (the H3-T6SS mutants) realized that this "foam" isn't just a weapon; it's also a fuel source and a shield.

The Story of the "Stealth Mutants"

Here is how the bacteria exploit the situation, step-by-step:

1. The Trap is Set
When the immune system attacks, it creates a tiny, acidic, low-oxygen room inside the macrophage called a phagolysosome. It's like a prison cell designed to dissolve the bacteria. The room is filled with itaconate.

2. The "Normal" Bacteria vs. The "Mutant"

• The Normal Bacteria (Wild Type): They try to fight back with their flamethrower (H3-T6SS). But in this cramped, acidic prison, the flamethrower is useless and actually makes them a bigger target. They get eaten.
• The Mutant Bacteria (H3-T6SS Defective): Because they don't have the flamethrower, they are quieter. They sense the itaconate and realize, "Hey, this prison cell is actually a buffet!"

3. The Metabolic Makeover
The mutant bacteria undergo a massive internal renovation. They switch their engines to run on the specific food available in the prison cell (lactate, purines, and glycerol).

• Analogy: Imagine a car designed for a highway (the normal bacteria). If you drive it into a muddy swamp, it gets stuck. The mutant bacteria are like a swamp-vehicle; they swap their tires and engine to run perfectly on mud. The itaconate acts as the "key" that unlocks this new engine mode.

4. The "Trojan Horse" Effect
Because the mutants are so good at surviving in this low-oxygen, acidic, itaconate-rich environment, they don't just survive; they thrive.

• They get eaten by the immune cells (phagocytosis) but refuse to die.
• They hide inside the immune cell's "prison cell" (phagolysosome).
• The itaconate actually helps the immune cell stay alive longer (by reducing stress), which accidentally gives the bacteria a longer, safer hiding spot.

Why Does This Matter?

This explains why some lung infections are so hard to cure.

• The Antibiotic Problem: Most antibiotics are designed to kill bacteria that are floating freely in the airways (like people walking down the street). They don't work well on bacteria hiding inside the immune cells (like people hiding in a bunker).
• The Evolution: Over time, in patients with chronic infections (like Cystic Fibrosis), the bacteria that keep their flamethrower die out. The ones that lose it and become "stealth mutants" survive and take over.
• The Result: The infection becomes "intractable" (impossible to treat) because the bacteria have adapted to live inside your own defense system, using your own chemicals (itaconate) to power their survival.

The Takeaway

The researchers found that losing a weapon can sometimes be a winning strategy.

By turning off the H3-T6SS system, Pseudomonas bacteria stop fighting the immune system head-on. Instead, they hijack the immune system's own chemical defenses (itaconate) to fuel their metabolism, allowing them to hide safely inside the very cells meant to destroy them. To cure these stubborn infections, doctors might need new drugs that can break into these "bunkers" or stop the bacteria from using itaconate as fuel.

Technical Summary

1. Problem Statement

Pseudomonas aeruginosa is a leading cause of persistent pulmonary infections (e.g., in Cystic Fibrosis and COPD patients) that are notoriously difficult to clear with standard antimicrobial therapy. While the Type 3 Secretion System (T3SS) is well-known for driving acute, fulminant sepsis, the role of the Type 6 Secretion System (T6SS) in chronic, indolent pulmonary infections remains poorly defined.

• The Gap: Clinical isolates from chronic infections frequently accumulate mutations, but the specific adaptive mechanisms allowing P. aeruginosa to persist within the hostile environment of the lung (specifically inside phagocytes) are unclear.
• The Hypothesis: The authors postulated that the loss of function of specific T6SS loci (specifically H3-T6SS) during chronic infection is an adaptive strategy that allows the bacteria to exploit host immunometabolites, particularly itaconate, to survive and replicate within phagocytes.

2. Methodology

The study employed a multi-disciplinary approach combining clinical genomics, murine infection models, transcriptomics, metabolomics, and cell biology.

• Clinical Genomics: Analysis of publicly available Whole Genome Sequencing (WGS) data from P. aeruginosa isolates recovered from Chronic Cystic Fibrosis (CF) patients versus Acute ICU pneumonia patients. The focus was on identifying mutations in the H1, H2, and H3 T6SS gene clusters.
• Mouse Models:
  • Used Wild-Type (WT) C57BL/6 mice and Irg1⁻/⁻ mice (lacking the enzyme Irg1/Acod1, which produces itaconate).
  • Inoculated mice intranasally with WT P. aeruginosa PAO1 or isogenic mutants lacking H1, H2, or H3 T6SS loci ($\Delta$H3-T6SS).
  • Measured bacterial loads, cytokine levels, and immune cell recruitment in the lungs.
• Bacterial Strains & Mutants: Generated markerless deletion mutants in the PAO1 background ($\Delta$vgrG1, $\Delta$H2-T6SS, $\Delta$H3-T6SS, $\Delta$ict).
• In Vitro Assays:
  • Growth Conditions: Tested bacterial growth under microaerobic (1% O₂), anaerobic, and low pH (pH 5.0) conditions, with and without itaconate.
  • Phagocytosis Assays: Used Bone Marrow-Derived Macrophages (BMDMs) from WT and Irg1⁻/⁻ mice, and the THP-1 human macrophage cell line.
  • Inhibitors: Used Bafilomycin A (vATPase inhibitor) to neutralize phagolysosomal pH.
• Omics Analysis:
  • Bulk RNA-Seq: Compared transcriptomes of WT vs. $\Delta$H3-T6SS grown in LB media with/without itaconate.
  • Metabolomics: Used LC-MS to analyze intracellular bacterial metabolites and bronchoalveolar lavage fluid (BALF) from infected mice.
• Imaging: Confocal microscopy to visualize bacterial colocalization with LAMP-1 (a phagolysosome marker) in both in vitro and in vivo (sorted alveolar macrophages) settings.

3. Key Contributions

1. Identification of H3-T6SS Loss as an Adaptive Trait: Demonstrated that loss-of-function mutations in the H3-T6SS cluster (specifically in clpV3 and vgrG3) are selected for in chronic CF infections but not in acute pneumonia.
2. Discovery of the Itaconate-Dependent Mechanism: Revealed that the enhanced virulence of H3-T6SS mutants is strictly dependent on host-derived itaconate. In the absence of itaconate (Irg1⁻/⁻ mice), the mutant advantage disappears.
3. Metabolic Reprogramming: Defined a specific metabolic shift in H3-T6SS mutants that allows them to utilize carbon sources abundant in the phagolysosome (lactate, purines, glycerol) and generate energy (ATP) under microaerobic conditions.
4. Paradoxical Role of Itaconate: Showed that while itaconate is an antimicrobial metabolite, it paradoxically supports the survival of these specific mutants by preserving macrophage viability (via antioxidant pathways) and acting as a metabolic trigger for bacterial adaptation.

4. Key Results

• Genomic Evidence: Chronic CF isolates showed a high frequency of missense and loss-of-function mutations in the H3-T6SS loci (clpV3, vgrG3), whereas acute ICU isolates retained functional H3-T6SS.
• In Vivo Virulence: The $\Delta$H3-T6SS mutant caused significantly higher bacterial loads in the lungs of WT mice compared to WT PAO1. This phenotype was abolished in Irg1⁻/⁻ mice (which cannot produce itaconate), proving the dependence on host itaconate.
• Transcriptomic Adaptation: In the presence of itaconate, the $\Delta$H3-T6SS mutant upregulated genes associated with:
  • Phagocytic uptake: anvM (interacts with the O2 sensor Anr).
  • Microaerobic respiration: mhr (microoxic hemerythrin), ccoN2 (cytochrome oxidase), and oprG.
  • Metabolism: Genes for lactate metabolism (lldA), glucuronate production (kguK, kguE), and purine metabolism (purE, purM).
• Intracellular Survival:
  • $\Delta$H3-T6SS mutants showed increased survival and colocalization with LAMP-1 (phagolysosome marker) in macrophages.
  • This advantage was lost in Irg1⁻/⁻ macrophages and when phagolysosomal acidification was blocked by Bafilomycin A, confirming adaptation to the low pH/low O2/high itaconate phagolysosome environment.
• Metabolic Mechanism:
  • Itaconate did not serve as a direct carbon source for the bacteria (mutants unable to metabolize itaconate still survived).
  • Instead, itaconate acted as a signaling molecule that boosted the bioenergetics of the $\Delta$H3-T6SS mutant.
  • The mutant showed increased levels of NADH/FADH2 and oxygen consumption rates (OCR) when grown with itaconate, allowing efficient use of available substrates (lactate, purines, glycerol) to generate ATP.
• Macrophage Viability: Itaconate was found to be critical for maintaining macrophage viability during infection by upregulating the antioxidant enzyme Hmox1 via the Nrf2 pathway. Without itaconate, macrophages underwent rapid cell death, clearing the bacteria.

5. Significance

• Redefining T6SS Function: This study shifts the paradigm of T6SS from a purely offensive weapon (interbacterial competition) to a regulator of metabolic versatility. The loss of H3-T6SS is not a defect but a strategic adaptation to the host environment.
• Mechanism of Persistence: It explains how P. aeruginosa persists in the lung despite antibiotic treatment. The bacteria sequester themselves within phagocytes (a "safe haven" where many antibiotics fail to penetrate) and utilize host immunometabolites to fuel their growth.
• Therapeutic Implications:
  • Standard antimicrobial susceptibility testing (based on planktonic growth in aerobic conditions) fails to predict the efficacy of drugs against these intracellular, metabolically adapted variants.
  • Targeting the specific metabolic pathways (e.g., lactate or purine metabolism) or the itaconate-mediated signaling axis could offer novel strategies to eradicate chronic P. aeruginosa infections.
• Host-Pathogen Interaction: Highlights the complex dual role of itaconate: it is a host defense molecule that clears some pathogens but inadvertently selects for and supports the survival of P. aeruginosa variants that have evolved to exploit it.

In conclusion, the paper demonstrates that P. aeruginosa evolves to lose the H3-T6SS to "unleash" a metabolic program that allows it to thrive in the itaconate-rich, microaerobic phagolysosome, turning a host defense mechanism into a niche for persistent infection.